
Loading, please wait...

Loading, please wait...

Serotonergic psychedelics fundamentally alter sensory perception, yet neuroscientists rarely study their specific influence on chemosensory navigation. Recent pre-clinical investigations demonstrate that psychedelic compounds significantly degrade olfactory search behavior while simultaneously altering motor patterns and active sniffing rhythms in murine models.
Animals rely heavily on chemical cues to locate food, identify mates, and avoid environmental hazards. Consequently, any acute perturbation of sensory gating impairs survival and spatial orientation. Classic psychedelics act primarily as potent agonists at serotonin 5-HT2A receptors throughout the central nervous system. While previous research focused extensively on visual distortions and cortical connectivity, researchers designed new behavioral assays to quantify chemical tracking. Specifically, investigators tested the synthetic phenethylamine psychedelic 2,5-dimethoxy-4-iodoamphetamine, commonly known as DOI, during complex odor-guided localization tasks. The resulting data indicate that DOI substantially reduces target acquisition accuracy. Moreover, treated animals spend significantly more time completing trials and exhibit altered trajectory paths compared to baseline controls. Thus, the compound appears to dissociate sensory input processing from goal-directed motor execution. Understanding these nuances helps neuropharmacologists map how serotonergic agonists reconfigure primary sensory channels beyond classic visual models.
During structured behavioral trials, mice navigated an open arena to identify specific odor plumes linked to rewards. Researchers administered DOI and tracked kinematic metrics alongside chemosensory decisions. Notably, DOI administration led to a marked drop in overall search precision. Treated mice frequently bypassed reward ports and required significantly longer durations to locate target odors. Furthermore, their velocity decreased noticeably, producing hesitant and fragmented movement trajectories throughout the arena. However, the animals did not display gross motor paralysis or total loss of motivation. Instead, they demonstrated exploratory persistence despite impaired accuracy. In addition, mice spent extended periods lingering inside reward ports before resuming movement. These quantitative observations demonstrate that the psychedelic selectively disrupts behavioral efficiency rather than general physical capability. Therefore, the impairment reflects a disruption in sensory computation and decision-making rather than simple locomotor failure.
The neurobiological basis of these changes stems from dense 5-HT2A receptor expression within sensory cortices and the olfactory bulb. Under normal conditions, neural gating filters irrelevant environmental noise to maintain sharp signal-to-noise ratios. However, DOI binding to cortical and bulbar interneurons induces spontaneous asynchronous firing. Consequently, this receptor activation destabilizes the temporal coordination required to interpret gradient concentrations. Moreover, pyramidal neuron excitability increases, which degrades top-down attentional control and sensory fidelity. As a result, the animal experiences sensory flooding and misinterprets incoming odorant gradients. Furthermore, classic thalamocortical gating models suggest that psychedelics impair sensory filtering across modalities. In this context, the olfactory system presents a unique architecture because it bypasses the thalamus during initial processing. Therefore, finding profound search degradation confirms that 5-HT2A-mediated disruption occurs directly within primary sensory structures and higher cortical association hubs.
Chemosensory navigation requires active sampling through precise respiratory modulation. Mice naturally adjust their sniffing frequency to sample odor plumes dynamically during active locomotion. Interestingly, the study revealed that DOI significantly increases basal and task-related sniff rates. Even though the animals sniffed faster, their spatial accuracy declined. This apparent paradox provides critical insight into sensory active sampling mechanisms. Specifically, the elevated sniffing rate indicates compensatory sampling efforts by the central nervous system. Because the internal representation of the odor is degraded, the animal increases sampling frequency to gather additional sensory evidence. However, hyper-sniffing fails to rescue behavioral performance because downstream cortical integration remains disorganized. Furthermore, altered respiratory rhythms disrupt the precise phase-locking between olfactory bulb local field potentials and respiratory cycles. Consequently, the timing of neural coding breaks down, preventing the animal from executing accurate navigational corrections.
These rodent findings offer valuable translational insights into human perceptual disorders and neuropsychiatric therapy. In clinical psychiatry, patients with schizophrenia, severe mood disorders, and substance-induced psychoses frequently report distorted sensory perceptions, including olfactory hallucinations and phantosmia. Furthermore, psychedelic-assisted psychotherapy is gaining substantial momentum for treating major depressive disorder and post-traumatic stress disorder. Clinicians must understand how 5-HT2A agonism alters multimodal sensory integration and active environmental sampling. Additionally, olfactory dysfunction serves as an established early biomarker in various neurodegenerative disorders like Parkinson disease. Investigating how serotonergic agonists modify chemosensory circuits illuminates the shared pathways underlying perception, mood regulation, and cognitive flexibility. Therefore, basic research into rodent chemosensation bridges critical knowledge gaps regarding human cortical microcircuits, perceptual stability, and pharmacological neuromodulation.
Subsequent research must explore whether selective 5-HT2A antagonists can reverse DOI-induced olfactory search deficits. Moreover, scientists should record simultaneous multi-unit activity across the olfactory bulb, piriform cortex, and orbitofrontal cortex during active tracking. Such electrophysiological experiments will clarify whether the sensory deficit arises from peripheral coding errors or impaired cortical decision thresholding. In addition, comparing DOI with other psychedelic classes, such as psilocin or lysergic acid diethylamide, will determine whether this phenomenon applies universally across all 5-HT2A agonists. Furthermore, dose-response studies are necessary to identify whether microdosing produces subtle sensory enhancement or uniform perceptual disruption. Ultimately, dissecting chemosensory behaviors in animal models enriches our foundational understanding of how psychedelic compounds reorganize mammalian perception and neural network dynamics.
DOI directly reduces navigation accuracy during scent-tracking tasks. In experimental models, mice treated with this 5-HT2A agonist take longer to locate odor targets, exhibit fragmented locomotor trajectories, and frequently overshoot reward zones. These deficits demonstrate that DOI disrupts sensory interpretation and decision-making without causing motor paralysis.
Sniffing represents an active sensory sampling behavior that controls how odor molecules reach receptor neurons. DOI increases sniff rates, reflecting compensatory sampling attempts by the animal. However, because downstream neural phase-locking and cortical processing are disorganized, this increased sampling fails to restore navigational precision.
Understanding 5-HT2A-mediated sensory changes informs human neuropsychiatry, particularly regarding sensory gating deficits in psychosis and therapeutic mechanisms in psychedelic medicine. These findings clarify how serotonergic agonists modify perceptual filters, providing translational insights into cortical connectivity, olfactory hallucinations, and cognitive network flexibility.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Refer to the latest local and national guidelines for clinical practice.
References
1. Welch AC et al. The impact of a psychedelic drug on olfactory search behavior by mice. Chem Senses. 2026 Aug 25. doi: undefined. PMID: 42641131.
2. Olson RJ et al. Decoupling of cortical activity from behavioral state following administration of the classic psychedelic DOI. Neuropharmacology. 2024;257:110030.
3. Findley TM et al. Sniff-synchronized, gradient-guided olfactory search by freely moving mice. Elife. 2021;10:e58833.

Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


A recent study explores the impact of the serotonergic psychedelic DOI on mouse chemosensation. The drug alters olfactory search behavior, increases sniffing frequency, and disrupts navigation accuracy, providing valuable insights into sensory processing and neuropsychiatric gating mechanisms.
Today

A scientometric analysis highlights the clinical evolution of engineered bacterial therapeutics from synthetic gene circuit design to targeted applications in oncology, gastroenterology, and live biotherapeutic products.
Today

A randomized controlled trial demonstrates that the Dyadic Guidance and Empowerment Program (D-GEP) significantly reduces demoralization, symptom burden, and caregiver strain among women with gynaecological cancer and their family caregivers during the hospital-to-home transition.
Today

Swallow-induced atrioventricular block is a rare, vagally mediated bradyarrhythmia. Selective cardioneuroablation targeting parasympathetic ganglionated plexi offers an effective, pacemaker-sparing intervention for patients refractory to conservative measures.
Today

A randomized controlled trial demonstrates that dorsolateral prefrontal cortex (DLPFC) targeted rTMS significantly reduces phantom limb pain while alleviating depression and anxiety in amputees, offering a safe, non-invasive neuromodulatory therapeutic option.
Today

Discover how passive sarcomere tension, microtubule networks, and diastolic crossbridges differentially drive cardiomyocyte diastolic stiffness in male versus female cardiometabolic HFpEF models.
Today